Easy To Use Patents Search & Patent Lawyer Directory

At Patents you can conduct a Patent Search, File a Patent Application, find a Patent Attorney, or search available technology through our Patent Exchange. Patents are available using simple keyword or date criteria. If you are looking to hire a patent attorney, you've come to the right place. Protect your idea and hire a patent lawyer.

Searching:





Search by keyword, patent number, inventor, assignee, city or state:




Patent # Description
2016/0272721 ANTIBODY SPECIFIC TO THE AIMP2-DX2
Described herein are an antibody specifically binding to AIMP2-DX2 protein, and a diagnostic kit for detecting cancer which comprises the antibody specific to...
2016/0272720 Compositions and Methods for the Treatment of Acute Myeloid Leukemias and Myelodysplastic Syndromes
Provided are compositions and methods for the treatment of hematological conditions, in particular CD99+ acute myelogenous leukemias (AML) and myelodysplastic...
2016/0272719 Antibody Glycosylation Variants Having Increased Antibody-Dependent Cellular Cytotoxicity
The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation...
2016/0272718 Smart CAR Devices, DE CAR Polypeptides, Side CARs and Uses Thereof
The present invention relates generally to the field of RNA Control Devices and/or destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs)...
2016/0272717 ANTI-GARP PROTEIN AND USES THEREOF
The present invention relates to an antibody binding to the transmembrane protein `glycoprotein A repetitions predominant` (GARP) in the presence of TGF-.beta....
2016/0272716 ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO FLT3 PROTEINS
Antibody drug conjugates (ADC's) that bind to FLT3 protein and variants thereof are described herein. FLT3 exhibits a distinct and limited expression pattern...
2016/0272715 TREATMENT OF C1013G/CXCR4-ASSOCIATED WALDENSTROM'S MACROGLOBULINEMIA WITH AN ANTI-CXCR4 ANTIBODY
The present disclosure provides a method for treating a subject afflicted with Waldenstrm's macroglobulinemia (WM) comprising administering to the subject a...
2016/0272714 Chemokine receptor binding polypeptides
The present invention relates to polypeptides directed against or specifically binding to chemokine receptor CXCR2 and in particular to polypeptides capable of...
2016/0272713 Fibrosis Inhibiting Compounds and Methods of Use Thereof in the Prevention or Treatment of Fibrosing Diseases
The present disclosure relates to a method of inhibiting fibrocyte or profibrotic macrophage formation by administering a CD209-binding compound or antibody to...
2016/0272712 ANTI-PD-L1 MONOCLONAL ANTIBODIES AND FRAGMENTS THEREOF
The present invention is based, in part, on the discovery of monoclonal antibodies that specifically bind to the cytoplasmic domain of PD-L1 antibodies useful...
2016/0272711 Agents for Treatment of Claudin Expressing Cancer Diseases
The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is...
2016/0272710 Targeting Tissue Factor To Activated Platelets
The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins....
2016/0272709 ANTI-KIR ANTIBODIES
Provided herein are compositions (e.g., killer cell immunoglobulin-like receptor (KIR)-targeting agents) that target a subset of T lymphocytes present in...
2016/0272708 ANTI-PD-1 ANTIBODY AND USE THEREOF
This invention provides antibodies or functional fragments thereof that bind to PD-1 with high affinity. The invention provides nucleic acid molecules encoding...
2016/0272707 VSTM5 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER, INFECTIOUS DISEASES AND IMMUNE RELATED DISEASES
The present invention relates to VSTM5-specific antibodies, antibody fragments, and VSTM5 polypeptides, conjugates and compositions comprising same, for...
2016/0272706 IL-13 BINDING PROTEINS AND USES THEREOF
Novel anti-IL-13 antigen-binding proteins such as antibodies and antigen-binding fragments thereof are provided. Methods of using the proteins to reduce IL-13...
2016/0272705 COMPOSITIONS FOR SELECTIVE REDUCTION OF CIRCULATING BIOACTIVE SOLUBLE TNF AND METHODS FOR TREATING TNF-MEDIATED...
An isolated or synthetic antibody or ligand is provided that specifically binds to an epitope of a dissociated monomer of human TNF. Such binding disrupts...
2016/0272704 Use of TNFalpha Inhibitor
The invention describes methods of treating erosive polyarthritis comprising administering a TNF.alpha. antibody, or antigen-binding portion thereof. The...
2016/0272703 TNF-ALPHA BINDING PROTEINS
TNF-.alpha. binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-.alpha. are provided. Binding proteins have high affinity...
2016/0272702 ANTI-CCL8 THERAPY FOR BREAST CANCER
Methods and materials for prevention of migration of breast cancer cells are described. Methods include inhibition of CCL8 activity in the area of the breast...
2016/0272701 ANTI-NERVE GROWTH FACTOR ANTIBODIES AND METHODS OF PREPARING AND USING THE SAME
A method of preparing an antibody suitable for use in a feline is provided. Also provided are chimeric and felinised antibodies which specifically bind to...
2016/0272700 HIGH CONCENTRATION FORMULATIONS OF ANTI-C5 ANTIBODIES
The present disclosure relates to, inter alia, stable aqueous solutions comprising a high concentration of an antibody that binds to human complement component...
2016/0272699 HUMANIZED ANTIBODY
The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of...
2016/0272698 REGULATING BACILLUS ANTHRACIS LETHAL FACTOR ACTIVITY VIA AN ACTIVATING EPITOPE REGION
Provided are antibodies capable of binding to a particular epitope or specifically binding to LF or LTx and enhancing the activity of the LF or LTx relative to...
2016/0272697 Neutralizing Antibodies to Nipah and Hendra Virus
The invention described herein provides novel peptides. The novel peptides are useful alone or as portions of larger molecules, such as antibodies or antibody...
2016/0272696 PRODUCTION OF RECOMBINANT PROTEINS WITH SIMPLE GLYCOFORMS
The present invention provides cell lines deficient in mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase I (Mgat1). Also provided are...
2016/0272695 CD27 SINGLE CHAIN MOLECULES
The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules...
2016/0272694 COMPOSITIONS AND METHODS FOR THE TREATMENT OF ECTODERMAL DYSPLASIA
The invention relates to pharmaceutical compositions and methods for the treatment of ectodermal displasias via the administration of EDA agonists, in...
2016/0272693 AMYLIN ANALOGUES
The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including...
2016/0272692 CDCA1 EPITOPE PEPTIDES AND VACCINES CONTAINING THE SAME
Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from CDCA1 that elicit CTLs. The...
2016/0272691 COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH y-HERPESVIRUSES
One object of certain embodiments of the present invention is therapeutic agents and compositions to treat conditions associated with activation of yHV. In...
2016/0272690 YAP PROTEIN INHIBITING POLYPEPTIDE AND APPLICATION THEREOF
Provided in the present invention are a YAP protein inhibiting polypeptide and application thereof. In particular, the present invention obtains a key binding...
2016/0272689 PROTAMINE IN TREATMENT OF NEURONAL INJURIES
The present invention relates to treatment of neuronal injury. The present invention discloses a novel use of an agent and a novel method for promoting neurite...
2016/0272688 STREPTAVIDIN MUTEINS AND METHODS OF USING THEM
The invention concerns novel streptavidin muteins. In one embodiment such a mutein (a) contains at least one mutation in the region of the amino acid positions...
2016/0272687 ADENO-ASSOCIATED VIRUS "X" ONCOGENE
A novel gene "X" of adeno-associated virus is presented, which is found to be an oncogene and to promote efficient production of recombinant AAV virus...
2016/0272686 APPROACH TO PRODUCE HIV-1 GP140 ENVELOPE PROTEIN TRIMERS
An approach of producing recombinant trimers that mimic native HIV-1 envelope trimers is developed. A recombinant protein forming the recombinant trimers...
2016/0272685 APPROACH TO PRODUCE HIV-1 GP140 ENVELOPE PROTEIN TRIMERS
An approach of producing recombinant trimers that mimic native HIV-1 envelope trimers is developed. A recombinant protein forming the recombinant trimers...
2016/0272684 APPROACH TO PRODUCE HIV-1 GP140 ENVELOPE PROTEIN TRIMERS
An approach of producing recombinant trimers that mimic native HIV-1 envelope trimers is developed. A recombinant protein forming the recombinant trimers...
2016/0272683 Novel Amylin And Calcitonin Receptor Agonist
The present invention relates to peptides comprising an amino acid sequence SEQ ID NO: 1 (EASELSTAALGRLSAELHELATLPRTETGPESP), analogues and derivatives thereof...
2016/0272682 GLYCOPEPTIDE ANTIBIOTIC ANALOGS EFFECTIVE AGAINST VANCOMYCIN-RESISTANT BACTERIAL STRAINS
The invention is directed to glycopeptide antibiotics and their aglycones that are engineered to overcome bacterial resistance by replacement of a single,...
2016/0272681 CYCLOSPORIN A FORM 2 AND METHOD OF MAKING SAME
Disclosed herein are methods of making cyclosporin A Form 2.
2016/0272680 Immunomodulators
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the...
2016/0272679 WNT FAMILY-DERIVED PEPTIDES AND USE THEREOF
The present invention relates to a WNT-derived novel peptide and use thereof. WNT-derived peptide of the present invention possesses identical or similar...
2016/0272678 INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES
In fibrotic lung fibroblasts, basal levels of p53 protein (and miR-34a) are markedly suppressed, leading to reduced p53-mediated inhibition of uPA and uPAR, or...
2016/0272677 PROCESS FOR THE PREPARATION OF DIFFERENT CRYSTALLINE FORMS OF S-ACETYL GLUTATHIONE, AND THEIR USES IN...
Disclosed are two novel crystalline forms of S-acetyl glutathione (SAG) called Form A and Form B, obtained by crystallisation of SAG from mixtures of...
2016/0272676 Protein Separations Using An Acrylamide Containing Filter
Novel compositions for re-moving impurities such as, protein aggregates, from a sample containing a protein of interest, e.g., an antibody. Such compositions...
2016/0272675 Purification of Proteins
This application relates to methods for purification of proteins such as antibodies using a hydrophilic polymer (e.g., PEG), a fatty acid (e.g., caprylic...
2016/0272674 ISOLATION AND PURIFICATION OF ANTIBODIES
Embodiments of the present invention are directed to high throughput flow through purification of antibodies using mixed mode chromatography.
2016/0272673 ISOLATION AND PURIFICATION OF DVD-IGS
Chromatographic methods for isolating and purifying DVD-lgs.TM. from a sample, wherein the purified DVD-lgs.TM. have reduced host cell proteins, aggregates,...
2016/0272672 PHOTOLABILE LINKER FOR THE SOLID-PHASE SYNTHESIS OF HYDRAZIDES AND PYRANOPYRAZOLES
The photolabile hydrazine linker of the present invention is based on the o-nitro-veratryl group, which is capable of releasing hydrazide derivatives upon UV...
← Previous | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 | Next →

File A Patent Application

  • Protect your idea -- Don't let someone else file first. Learn more.

  • 3 Easy Steps -- Complete Form, application Review, and File. See our process.

  • Attorney Review -- Have your application reviewed by a Patent Attorney. See what's included.